Skip to main content

TNF inhibitor

      RT @doctorRBC: Drug retention of TNFi vs. secukinumab in AxSpA pts
      Abs#911
      ⭐️46% discontinued either treatment
      ⭐ï

      Robert B Chao, MD doctorRBC

      3 years 6 months ago
      Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
      RT @swethaann23: ⭐️Prevalent drug utilization was not related to enthesitis activity
      ⭐️Prevalent use of cDMARDs

      swethaann23 swethaann23

      3 years 6 months ago
      ⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
      Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annu

      Dr. John Cush RheumNow

      3 years 6 months ago
      Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting. https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
      RT @drdavidliew: Put those two RF together (essentially nailing down RA pts at risk of cancer):

      age >65 or ever smok

      David Liew drdavidliew

      3 years 6 months ago
      Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
      Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
      RT @RichardPAConway: Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disea

      Richard Conway RichardPAConway

      3 years 6 months ago
      Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disease control. Consistent across all rheumatic and non-rheumatic diseases. Abstr#1946 #ACR21 @RheumNow https://t.co/D1Ppb58fB8
      RT @RichardPAConway: ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared

      Richard Conway RichardPAConway

      3 years 6 months ago
      ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
      RT @drdavidliew: ORAL Surveillance: MACE and malignancy are getting all the attention...

      but did you know that non-zost

      David Liew drdavidliew

      3 years 6 months ago
      ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
      RT @Janetbirdope: Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. No

      Janet Pope Janetbirdope

      3 years 6 months ago
      Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC
      RT @uptoTate: Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or i

      Dr. Rachel Tate uptoTate

      3 years 6 months ago
      Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn
      RT @DrPetryna: Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additio

      Olga Petryna DrPetryna

      3 years 6 months ago
      Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additional biologic trial. Former smoker &PsA duration correlated w/ discontinuation. most commonly reason for d/c TNFi was secondary failure (33%). infliximab had lower d/c rate https://t.co/BXd2ALX2qo
      RT @uptoTate: Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs

      Dr. Rachel Tate uptoTate

      3 years 6 months ago
      Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
      ×